Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine Monohydrate for Preventing Altitude Induced Depression
NCT03433651Phase 4Withdrawn
- Sponsor
- Mike O'Callaghan Federal Medical Center
- Start
- Jan 2019
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of creatine in major depressive disorder (MDD), sponsored by Mike O'Callaghan Federal Medical Center. Planned start Jan 2019; status: withdrawn.
02
Drugs
creatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03433651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03433651.